Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 924 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 924 shares of the business’s stock in a transaction on Friday, October 18th. The shares were sold at an average price of $30.00, for a total transaction of $27,720.00. Following the transaction, the chief executive officer now owns 1,002,892 shares of the company’s stock, valued at $30,086,760. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Samuel Kintz also recently made the following trade(s):

• On Wednesday, October 9th, Samuel Kintz sold 16,710 shares of Enliven Therapeutics stock. The shares were sold at an average price of $28.15, for a total transaction of $470,386.50.
• On Monday, October 7th, Samuel Kintz sold 2,730 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.50, for a total transaction of $75,075.00.
• On Friday, October 4th, Samuel Kintz sold 12,206 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.51, for a total transaction of $335,787.06.
• On Tuesday, October 1st, Samuel Kintz sold 526 shares of Enliven Therapeutics stock. The shares were sold at an average price of $27.54, for a total transaction of $14,486.04.
• On Monday, August 26th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.89, for a total transaction of $274,680.00.
• On Wednesday, July 31st, Samuel Kintz sold 2,270 shares of Enliven Therapeutics stock. The stock was sold at an average price of $27.56, for a total transaction of $62,561.20.
• On Thursday, July 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $24.92, for a total transaction of $299,040.00.

Enliven Therapeutics Price Performance

NASDAQ ELVN traded up $0.08 during trading hours on Tuesday, hitting $28.95. 152,952 shares of the company’s stock traded hands, compared to its average volume of 260,665. The firm’s 50-day moving average is $24.23 and its 200-day moving average is $22.77. Enliven Therapeutics, Inc. has a 52-week low of $9.80 and a 52-week high of $30.03. The company has a market capitalization of $1.36 billion, a PE ratio of -14.96 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Tuesday, August 13th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. Equities research analysts predict that Enliven Therapeutics, Inc. will post -1.98 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Quest Partners LLC grew its position in Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after purchasing an additional 742 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Enliven Therapeutics by 44.7% in the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock worth $646,000 after acquiring an additional 8,540 shares during the period. EntryPoint Capital LLC acquired a new stake in shares of Enliven Therapeutics in the 1st quarter worth $167,000. SG Americas Securities LLC acquired a new stake in shares of Enliven Therapeutics in the 3rd quarter worth $256,000. Finally, Rhumbline Advisers lifted its stake in shares of Enliven Therapeutics by 29.9% in the 2nd quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock worth $1,160,000 after acquiring an additional 11,420 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 target price on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.